Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer
Japanese Journal of Clinical Oncology · 2024
DOI: 10.1093/jjco/hyae010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Mukaddes Yılmaz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cumhuriyet University Faculty of Medicine, Department of Medical Oncology, Sivas. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Receptors, Estrogen, Receptors, Progesterone. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
In the current study, the effect of hormone receptor (HR) status on clinical and survival in early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer was investigated.
Methods
Two hundred ninety-one patients with HER2- positive were examined in two categories as HR-positive and HR-negative.
Results
Of these, 197 (68%) were HR-positive and 94 (32%) were HR-negative with a mean follow-up period of 68 ± 2.7 months. The groups were found to be similar in terms of age, menopausal status, comorbidity, pathologic type, stage, T stage, N stage, lymphovascular invasion, presence and percentage of intraductal component, multicentricity/focality and extracapsular invasion. Family history (P = 0.038), stage 2 tumor rate (P < 0.001), and perineural invasion (P = 0.005) were significantly higher in the HR-positive group. In the HR-negative group, mean Ki-67 value (P = 0.014), stage 3 tumor rate (P < 0.001), tumor necrosis (P = 0.004) and strong (3+) HER2 staining on immunohistochemical staining (P = 0.003) were higher. The incidence of relapse and metastasis, and the localization of metastasis were similar in both patient groups. The rate of locoregional relapse during the first 2 years was higher in the HR-negative patients than in the HR-positive patients (P = 0.023). Overall survival (OS) and disease-free survival (DFS) did not differ between the groups in univariate analysis. However, HR status was determined as an independent prognostic factor (HR: 2.11, 95% CI: 1.17–3.79; P = 0.012) for OS was not found to be significant for DFS in multivariate analysis.
Conclusion
Both clinicopathologic features and OS outcomes of HR-negative patients were worse than those of HR-positive patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cumhuriyet University Faculty of Medicine, Department of Medical Oncology, Sivas.
- Cumhuriyet University Faculty of Medicine, Department of Radiation Oncology, Sivas.
- Department of Medical Oncology, Acıbadem Hospital, Kayseri.
- Department of Medical Oncology, Medicana Hospital, Department of Medical Oncology, Medicana Hospital, Sivas, Turkey.
ORCID-Profile: Mukaddes Yılmaz
Zitieren
APA
Yılmaz, M., Erdiş, E., Uçar, M., Demir, N., Alandağ, C., & Yücel, B. (2024). Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae010
Vancouver
Yılmaz M, Erdiş E, Uçar M, Demir N, Alandağ C, Yücel B. Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer. Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae010
BibTeX
@article{Ylmaz2024,
author = {Yılmaz, Mukaddes and Erdiş, Eda and Uçar, Mahmut and Demir, Necla and Alandağ, Celal and Yücel, Birsen},
title = {Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer},
journal = {Japanese Journal of Clinical Oncology},
year = {2024},
doi = {10.1093/jjco/hyae010}
}
EUVIMED